Guidelines

• NCCN Guidelines Version 4.2023

Evidence Blocks

• NCCN Guidelines with Evidence Blocks Version 4.2023

Frameworks

• Basic Resources (English) Version 4.2022

• Core Resources (English) Version 4.2022

• Enhanced Resources (English) Version 4.2022

Guidelines for Patients

• Invasive Breast Cancer-English Version 2023

• Metastatic Breast Cancer-English Version 2023

• DCIS Breast Cancer-English Version 2023

• Inflammatory Breast Cancer-English Version 2023

• DCIS Breast Cancer-Spanish - Latin America Version 2023

• Metastatic Breast Cancer-Spanish - Latin America Version 2023

• Invasive Breast Cancer-Spanish - Latin America Version 2023

• Inflammatory Breast Cancer-Spanish - Latin America Version 2023

• Metastatic Breast Cancer-Ukrainian Version 2020

• DCIS Breast Cancer-Ukrainian Version 2020

• Invasive Breast Cancer-Ukrainian Version 2020

Educational Events and Programs

Calendar of Events

Continuing Education

• Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for the Treatment of Metastatic Breast Cancer

• Archived Monthly Oncology Tumor Boards: Management of Early Stage Breast Cancer

• NCCN Pharmacy Updates: The Role of PD-L1 Therapy in the Early Treatment of Triple Negative Breast Cancer

• Disparities in Breast Cancer Screening and Management

• Neoadjuvant/Adjuvant Treatment for Breast Cancer with SABCS Updates

• Locoregional Management of Non-Invasive and Invasive Non-Metastatic Breast Cancer with SABCS Updates

• Multigene and Biomarker Testing in Breast Cancer: What is the Role?

• Breast Cancer Survivorship: The Importance of a Healthy Lifestyle

• Advances in the Management of Metastatic Breast Cancer with SABCS Updates

• Recognizing Bias and Health Care Disparities in Black Patients

• Diagnosis and Management of Breast Cancer: What does the Evidence Show, What are We Doing, And What’s on the Horizon?

• Comorbidities, Dosing Issues, Polypharmacy, and Adverse Effects in Breast Cancer

• Advances in the Management of Metastatic Breast Cancer

• Challenging Case Review: Breast Cancer

International

Disclosures

• Disclosure Policy

• Panel Member Disclosures

• Panel Member Disclosures by Meeting Date

• End User License Agreement